FLT3 and acute myeloid leukemia: Midostaurin in combination with standard chemotherapy demonstrated improved overall survival in newly diagnosed FLT3-mutated AML [36], while gilteritinib showed superiority over salvage chemotherapy in relapsed/refractory disease [37].